---
layout: default
title: Genesis Network – Prompt – Med Bay Diagnostic Bed Full Specification
description: Comprehensive prompt defining the full specification for the Med Bay Diagnostic Bed in the Genesis Network, incorporating all non-invasive and minimally invasive scanning enhancements, environmental sensors, variants for different settings, integration with the Communicator Badge ecosystem, and future iterations (February 2026 baseline).
license: Creative Commons Attribution 4.0 International (CC BY 4.0)
---

# Prompt – Genesis Network: Med Bay Diagnostic Bed Full Specification

**© 2025–2026 EarthStar Technologies** – Licensed under CC BY 4.0  
https://creativecommons.org/licenses/by/4.0/

## Objective

Define the complete specification for the **Med Bay Diagnostic Bed**, a modular, non-invasive (and minimally invasive patch-supported) diagnostic platform deployed in **[TerraWell FreeCare LLC](innovation-hub/terrawell-freecare-llc.md)** facilities, ambulances, assisted living centers, and future home variants. The bed integrates with the **[Communicator Badge](components/badges/communicator-badge.md)** and **[digital twins](docs/digital-twins.md)** for continuous, proactive health monitoring and early detection of metabolic, cardiovascular, neurological, oncologic, respiratory, infectious, musculoskeletal, and environmental exposure conditions.

This prompt consolidates **all enhancements** to date, including:
- All non-invasive imaging/scanning methods
- Minimally invasive patch-based biomarker analysis
- Environmental sensors for exposure tracking
- Variants for hospital, ambulance, assisted living, and home use
- Full integration with the badge ecosystem

## Core Design Principles

1. **Non-Invasive Priority** — Maximize diagnostic capability without radiation or skin penetration where possible.
2. **Minimally Invasive Support** — Use patch-based microneedle/interstitial fluid sampling only when required for high-accuracy biomarkers.
3. **Modular & Tile-Based** — All structural and sensor components built from **[toughened ceramic tiles](components/tiles/exterior-cladding.md)** and **[pods](components/pods/)** for repairability and waste-derived manufacturing.
4. **All-Electric Power** — Sodium-ion batteries + BIPV/piezo generation; biogas methane backup only.
5. **Privacy-First & Local Processing** — Data handled by **[OS & Software LLC](innovation-hub/os-software-llc.md)** edge AI; opt-in only for **[digital twins](docs/digital-twins.md)** sync.
6. **Standards Compliance** — ISO/TC 268 (smart cities), ISO 14001 (environmental), IEC 60601 (medical electrical), FDA Class II/III pathways.

## Full Non-Invasive Scanning Suite

| Scan Type                    | Technology / Method                     | Resolution / Sensitivity | Primary Targets | Bed Integration | Tricorder/Handheld Variant | Timeline (Mature) | Per-Bed Cost Estimate |
|------------------------------|-----------------------------------------|--------------------------|-----------------|-----------------|----------------------------|-------------------|------------------------|
| Ultrasound (Phased-Array)    | Piezoelectric transducers               | 0.1–1 mm                 | Soft tissue, organs, blood flow, heart, joints | Full-body probe array | Portable probe             | 2027–2029         | $5k–$15k              |
| Low-Field MRI (ULF 0.064–0.1 T) | Permanent magnet + AI reconstruction    | 2–5 mm                   | Brain, organs, joints, tumors, inflammation | Bed-embedded coils | Not feasible               | 2030–2035         | $100k–$500k           |
| Low-Dose CT (Photon-Counting) | X-ray + photon-counting detectors       | 0.3–0.6 mm               | Bone, lung, trauma, vessels | Bed gantry (mobile) | Not feasible               | 2030–2035         | $200k–$600k           |
| NIR Spectroscopy / Diffuse Optical | Near-infrared light (650–950 nm)        | Tissue depth 1–3 cm      | Oxygenation, hemoglobin, tumor hypoxia | Bed-mounted arrays | Handheld probe             | 2028–2030         | $5k–$20k              |
| Microwave / mmWave Imaging   | Microwave tomography / radar            | Shallow tissue (1–5 cm)  | Breast, skin, lung surface, hydration | Bed surface array | Handheld antenna           | 2030–2035         | $10k–$40k             |
| Thermal / Infrared Imaging   | IR camera (8–14 μm)                     | Surface temp ±0.1°C      | Inflammation, circulation, infection | Bed overhead camera | Handheld IR camera         | 2027–2029         | $2k–$10k              |
| Electrical Impedance Tomography (EIT) | Electrode array + current injection     | Lung/tissue conductivity | Pulmonary edema, ventilation | Bed electrode grid | Limited                    | 2029–2033         | $10k–$30k             |
| Photoacoustic Imaging        | Laser + ultrasound detection            | Vascular, oxygenation    | Tumors, brain oxygenation | Bed laser/ultrasound array | Handheld probe             | 2032–2038         | $20k–$80k             |
| Optical Coherence Tomography (OCT) | Near-infrared interferometry            | 1–2 μm resolution        | Skin, retina, mucosa | Bed-mounted scanner | Handheld probe             | 2028–2032         | $10k–$40k             |
| Terahertz Imaging            | Terahertz waves (0.1–10 THz)            | Shallow dielectric contrast | Burn depth, skin cancer | Bed surface array | Handheld                    | 2035–2040         | $30k–$100k            |

## Minimally Invasive Patch-Based Biomarkers

| Biomarker                    | Detection Method                        | Timeline (Mature) | Per-Patch Cost | Primary Screening Targets |
|------------------------------|-----------------------------------------|-------------------|----------------|----------------------------|
| Glucose                      | Enzymatic electrochemical               | 2027–2029         | $89–$199       | Diabetes, metabolic state |
| Ketones (β-Hydroxybutyrate)  | Enzymatic microneedle                   | 2030–2032         | $100–$250      | DKA risk, ketosis |
| Lactate                      | Enzymatic microneedle                   | 2030–2033         | $100–$250      | Fatigue, sepsis |
| Cortisol                     | Immunoassay microneedle                 | 2030–2033         | $120–$300      | Stress, burnout |
| Electrolytes (Na⁺, K⁺, Cl⁻)  | Ion-selective electrodes                | 2033–2037         | $150–$350      | Dehydration, renal risk |
| Cytokines (IL-6 proxy)       | Immunoassay microneedle                 | 2032–2036         | $150–$400      | Infection, inflammation |
| hs-CRP                       | Immunoassay                             | 2033–2037         | $180–$450      | Cardiovascular risk |
| Troponin (hs-cTn)            | Immunoassay microneedle                 | 2032–2036         | $180–$450      | Myocardial injury |
| NT-proBNP                    | Immunoassay microneedle                 | 2033–2037         | $200–$500      | Heart failure |

## Variants for Different Settings

| Variant                      | Target Setting                                | Key Features Included                     | Estimated Cost | Timeline | Primary Use Case |
|------------------------------|-----------------------------------------------|-------------------------------------------|----------------|----------|------------------|
| Hospital / Major TerraWell   | Full diagnostic centers                       | All non-invasive + minimally invasive     | $500k–$1.5M    | 2030–2035 | Comprehensive diagnostics |
| Ambulance / Mobile EMS       | Emergency vehicles                            | Ultrasound, thermal, NIR, low-dose CT (mobile) | $100k–$400k    | 2030–2035 | Field trauma/stroke assessment |
| Assisted Living              | Shared or per-resident beds                   | Ultrasound, thermal, NIR, bioimpedance    | $10k–$30k      | 2035–2040 | Continuous senior monitoring |
| Home Diagnostic Bed          | Individual home use                           | Bed-integrated ultrasound + thermal + NIR | $2k–$8k        | 2040–2050 | Daily health screening |

## Recomputed Financial Impact (Network-Wide, Mature Phase)

- **Total Additional CAPEX**: $150–$400M (2027–2040) for variants and miniaturization
- **Revenue Uplift**:
  - Assisted living contracts: +$300–$900M/year
  - Home consumer sales/subscriptions: +$400–$1,200M/year
  - EMS/hospital partnerships: +$200–$600M/year
- **Total Annual Uplift**: **+$900–$2,700M/year**
- **IRR Impact**: +12–20% (network overall 35–50% → 47–70%)
- **Viability Uplift**: +20–30% (widespread preventive diagnostics in homes/assisted living → massive reduction in acute care needs)

**CC-BY-4.0**  
Share & adapt freely with attribution to “Genesis Network concept – EarthStar Technologies” + source link.
